The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis

作者：Xiaomin Fu, Fanghui Li, Hongqin You, Benling Xu, Tingjie Wang, Peng Qin, Lu Han, Yong Zhang, Fang Zhang, Lingdi Zhao, Baozhen Ma, Yiman Shang, Yonghao Yang, Zibing Wang, Jinrong Qu, Quanli Gao · 发表于：Scientific Reports · 年份：2025 · DOI：10.1038/s41598-025-02597-5 · 被引用次数：8 · 研究领域：Cancer Immunotherapy and Biomarkers、CAR-T cell therapy research、Lymphoma Diagnosis and Treatment

More promising, effective, and less-invasive biomarkers for PD(L)-1 targeted responses, immune-related adverse events (irAEs), and prognosis are being explored. We conducted a single-center retrospective study in pan-cancer patients with anti-PD(L)-1 monotherapy. Observational endpoints included treatment response, prognosis, and irAEs. Peripheral blood immunophenotypes were analyzed by Flow Cytometry. 104 patients were enrolled. Higher pretreatment percentages of CD3 + CD4 + Th cells were associated with both responses (HR: 6.170, P = 0.034) and prognosis (HR: 1.930, P = 0.022). The higher baseline percentage of CD16 + CD56 + NK cells was positively correlated with response (HR: 3.730, P = 0.050) and negatively related to irAEs (HR: 0.460, P = 0.012). Decreased pretreatment CD3 + T cell counts were related to more irAEs (HR: 0.970, P = 0.026), while the percentage of CD3 + T cells was negatively associated with prognosis (HR: 1.930, P = 0.022). The higher baseline cell counts of CD3 + CD8 + CTL, CD19 + B, and the percentage of CD19 + B cells might be related to more irAEs ( P < 0.05). Significant correlation between duration of treatment (DOT) and prognosis, irAE and outcome was also confirmed ( P < 0.0001). Our findings confirmed multiple baseline circulating immunophenotype characteristics were related to PD(L)-1 targeted response, irAE onset, and prognosis.